Top

Published in:

01-01-2014 | Research Article

Overexpression of MACC1 protein and its clinical implications in patients with glioma

Authors: Tao Yang, Bin Kong, Yong-Qin Kuang, Lin Cheng, Jian-Wen Gu, Jun-Hai Zhang, Hai-Feng Shu, Si-Xun Yu, Wei-Qi He, Xue-Min Xing, Hai-Dong Huang

Published in: Tumor Biology | Issue 1/2014

Abstract

Metastasis associated in colon cancer 1 (MACC1) has been regarded as a novel potential therapeutic target for multiple cancers. However, the impact of MACC1 in glioma remains unclear. The aim of this study was to analyze the correlation of MACC1 expression with the clinicopathological features of glioma. MACC1 mRNA and protein expression levels in human glioma tissues were detected by quantitative real-time polymerase chain reaction and immunohistochemistry assays, respectively. MACC1 mRNA and protein expression were both significantly higher in glioma tissues than in corresponding noncancerous brain tissues (both P < 0.001). In addition, statistical analysis suggested that high MACC1 expression was significantly correlated with advanced pathological grade (P = 0.004) and that patients with high expression of MACC1 protein exhibited a poorer prognosis than those with low MACC1 expression. Furthermore, Cox multivariate analysis showed that MACC1 overexpression was an independent prognostic factor for predicting the overall survival of glioma patients. In conclusion, expression of MACC1 in glioma could be adopted as a candidate biomarker for the diagnosis of clinical stage and for assessing prognosis, indicating for the first time that MACC1 may play an important role in the tumor development and progression in glioma. MACC1 might be considered as a novel therapeutic target against this cancer.

Liu X, Tang H, Wang Z, Huang C, Zhang Z, She X, et al. F10 gene hypomethylation, a putative biomarker for glioma prognosis. J Neurooncol. 2012;107:479–85. doi:10.1007/s11060-011-0775-2.PubMedCrossRef

Rousseau A, Mokhtari K, Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system—what has changed? Curr Opin Neurol. 2008;21:720–7. doi:10.1097/WCO.0b013e328312c3a7.PubMedCrossRef

Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol. 2003;30:4–9.PubMedCrossRef

Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.PubMedCrossRef

Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14:130–8. doi:10.1158/1078-0432.CCR-07-0862.PubMedCrossRef

Tabatabai G, Hegi M, Stupp R, Weller M. Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Curr Neurol Neurosci Rep. 2012;12:302–7. doi:10.1007/s11910-012-0263-x.PubMedCrossRef

Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15:59–67. doi:10.1038/nm.1889.PubMedCrossRef

Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 2009;41:2356–9. doi:10.1016/j.biocel.2009.08.001.PubMedCrossRef

Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M, et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg. 2013;257:1089–95. doi:10.1097/SLA.0b013e31828f96bc.PubMedCrossRef

10.

Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, et al. MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res. 2010;30:3441–4.PubMed

11.

Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011;31:1141–5.PubMed

12.

Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg. 2011;141:895–8. doi:10.1016/j.jtcvs.2010.09.044.PubMedCrossRef

13.

Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, et al. MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res. 2011;31:777–80.PubMed

14.

Xie C, Wu J, Yun J, Lai J, Yuan Y, Gao Z, et al. MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS One. 2013;8:e64235. doi:10.1371/journal.pone.0064235.PubMedCentralPubMedCrossRef

15.

Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye C, et al. Overexpression of MACC1 and its significance in human breast cancer progression. Cell Biosci. 2013;3:16. doi:10.1186/2045-3701-3-16.PubMedCentralPubMedCrossRef

16.

Yang YP, Qu JH, Chang XJ, Lu YY, Bai WL, Dong Z, et al. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med. 2013;11:41. doi:10.1186/1479-5876-11-41.PubMedCentralPubMedCrossRef

17.

Stein U, Dahlmann M, Walther W. MACC1-more than metastasis? Facts and predictions about a novel gene. J Mol Med (Berl). 2010;88:11–8. doi:10.1007/s00109-009-0537-1.CrossRef

Title: Overexpression of MACC1 protein and its clinical implications in patients with glioma
Authors: Tao Yang
Bin Kong
Yong-Qin Kuang
Lin Cheng
Jian-Wen Gu
Jun-Hai Zhang
Hai-Feng Shu
Si-Xun Yu
Wei-Qi He
Xue-Min Xing
Hai-Dong Huang
Publication date: 01-01-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1112-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells

The association of SIPA1 gene polymorphisms with breast cancer risk: evidence from published studies

X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis

YKL-40 expression could be a poor prognostic marker in the breast cancer tissue

Association between vestibular schwannomas and mobile phone use

Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring

Keynote webinar | Spotlight on antibody–drug conjugates in cancer